The purpose of this study was to evaluate the prognostic importance of novel markers of renal dysfunction among patients with acutely destabilized heart failure (ADHF).
high prognostic value in cardiovascular disease, including ADHF (5-13). ␤-trace protein (BTP) is a low molecular mass protein belonging to the lipocalin protein family that has been established as an accurate marker of cerebrospinal fluid leakage (14) . Furthermore, it has also been recently described as a more sensitive marker than serum creatinine in detecting impaired renal function, with performance comparable to that of cystatin C (15) (16) (17) . The prognostic role of plasma BTP in hospitalized patients with ADHF has not been previously studied, and its comparative value to cystatin C or conventional measures of renal function in these patients is not known. Therefore, in this prospective study of hospitalized patients with ADHF, we aimed to assess the prognostic value of BTP and cystatin C relative to more conventional measures of renal function.
Methods

Study population and design. From September 2006 to
March 2009, we prospectively enrolled 220 consecutive patients admitted with an established final diagnosis of ADHF (diagnosed clinically using current guidelines [1] ) to the Department of Cardiology at Virgen de la Arrixaca University Hospital (Murcia, Spain). Blood samples were collected for all patients on arrival at the emergency department. Baseline clinical characteristics and hospital events were prospectively recorded. Echocardiography was also performed on all patients before hospital discharge. Left ventricular ejection fraction was measured using Simpson's biplane method. All patients received standard heart failure (HF) management, as recommended by contemporary guidelines (1) . During the entire hospitalization period, clinical management decisions about each patient were made by the cardiologist responsible, who was unaware of the patient's BTP and cystatin C concentrations.
Determination of both BTP and cystatin C levels was performed using a BN ProSpec analyzer (Dade Behring GmbH, Liederbach, Germany). The intra-assay and interassay coefficients of variation for BTP were 2.8% and 4.7%, respectively. The intra-assay and interassay coefficients of variation for cystatin C were 2.5% and 2.0%, respectively. Conventional measures of renal function included serum creatinine, eGFR (calculated using the simplified Modification of Diet in Renal Disease equation: 186.3 ϫ plasma creatinine Ϫ 1.154 ϫ age Ϫ 0.203; the correction factor for women was 0.742) (18) , and BUN. Follow-up and clinical end point. We examined worsening renal function (defined as a maximum increase in serum creatinine during hospitalization of Ն0.3 mg/dl [19] ) as a function of BTP or cystatin C concentrations; results were compared with creatinine, eGFR, and BUN. For the primary outcome measure as the combination of mortality and/or HF hospitalization, all patients were clinically followed during a median of 500 days (interquartile range 231 to 796). Death was ascertained from available medical records and death certificates. If hospital records were ambiguous or unavailable, National Death Records were consulted. In patients requiring hospitalization, medical records were carefully reviewed to further characterize the cause of hospitalization. The study was approved by the local ethics committee, and informed consent was obtained from each patient at inclusion. Statistical analysis. Continuous variables were tested for a normal distribution by the Kolmogorov-Smirnov test. Normally distributed data are presented as the mean Ϯ SD and non-normally distributed data as the median (interquartile range, interquartile data). Categorical variables are expressed as percentages. Categorized analyses were performed according to the presence of adverse clinical events during the follow-up. Differences in baseline characteristics were compared using the Student t test or the MannWhitney U test for continuous variables and the chi-square test for categorical variables. Relationships between BTP, cystatin C, and other clinical and analytical parameters were assessed by Spearman rank correlation. Univariable and multivariable logistic regression analyses were used to examine associations between variables and worsening renal function. To contrast prognostic accuracy, statistical comparison of receiver-operating characteristic curves was performed. To compare different predictive values, we constructed areas under the receiver-operating characteristic curve for sensitivity, specificity, positive predictive value and negative predictive value. The best prognostic cutoff for survival status was defined as the highest product of sensitivity and specificity. Net reclassification improvement and integrated discrimination improvement were performed with biomarkers kept as dichotomous variables, as described by Pencina et al. (20) , where the categories of probability for events are defined based on prognostication scheme of the Heart Failure Survival Score (21) . We calculated hazard ratios (HRs) derived from the Cox regression analysis to identify predictors of mortality and/or HF hospitalization during follow-up. The independent effect of variables on prognosis was calculated using a Cox multivariable regression analysis, incorporating covariates with p values Ͻ0.10 in the univariable analysis. To avoid colinearity effects, due to their extremely high correlation (r Ͼ 0.80), serum creatinine and eGFR, as well as BTP and cystatin C, were not entered together in multivariate models. The cumulative incidence of all-cause death or HF hospitalization was estimated according to the Kaplan-Meier method, and the log-rank statistic was used for comparisons. Inc., Chicago, Illinois) and SAS software (version 9.2, SAS Institute Inc., Cary, North Carolina).
Results
Among the 220 subjects with ADHF, the median plasma BTP concentration was 0.97 mg/l (range 0.74 to 1.37 mg/l), the median plasma cystatin C concentration was 1.15 mg/l (range 0.90 to 1.59 mg/l), the median serum creatinine was 1.14 mg/dl (range 0.84 to 1.45 mg/dl), the median eGFR was 64 ml/min/1.73 m 2 (range 45 to 78 ml/min/1.73 m 2 ), and the median BUN was 24 mg/dl (range 18 to 34 mg/dl).
Plasma BTP concentration was positively correlated with cystatin C concentration (r ϭ 0.86; p Ͻ 0.001). Both plasma BTP and cystatin C concentrations were positively correlated with serum creatinine, BUN, age, New York Heart Association functional class, N-terminal pro-B-type natriuretic peptide (NT-proBNP), uric acid, troponin T, and C-reactive protein, whereas both were negatively correlated with eGFR, serum albumin, and hemoglobin. BTP and cystatin C concentrations were not correlated with body mass index or left ventricular ejection fraction (Table 1) .
Worsening renal function during hospital admission oc- During the study period (median 500 days; interquartile range 231 to 796 days), a total of 116 patients (53%) experienced adverse clinical events: 62 patients died and 76 patients were readmitted to the hospital because of HF decompensation. The distribution of characteristics and laboratory parameters according to the occurrence of adverse clinical events is shown in Tables 2 and 3 . Patients who experienced adverse clinical events during follow-up were more likely to be older and more likely to have had previous HF and poorer functional status, to need more frequent in-hospital inotropic support, and to have a higher rate of worsening renal function during the hospital admission.
Those who experienced adverse clinical events had higher plasma BTP concentration ( (Fig. 1B ) compared with those with no adverse clinical events. Serum creatinine, BUN, NT-proBNP, and troponin T levels were also higher among patients who experienced adverse clinical events, whereas the glucose level and eGFR were lower among these patients.
Tertile analyses of BTP and cystatin C concentrations examined as a function of adverse clinical event rates revealed that there was a graded increase in mortality and/or HF hospitalization with increasing concentrations of these markers (Fig. 2) .
To define the optimal prognostic accuracy of BTP values regarding survival of adverse clinical events, we performed receiving-operating characteristic curve analyses. For comparison, the same receiving-operating characteristic curve analyses were performed with cystatin C, eGFR, and BUN. As detailed in Table 4 Data are expressed as mean Ϯ SD or n (%). ACE ϭ angiotensin-converting enzyme; ARB ϭ angiotensin-receptor blocker; HF ϭ heart failure; NYHA ϭ New York Heart Association.
Baseline Laboratory Parameters as a Function of Mortality and/or HF Hospitalization 
when cystatin C was added to eGFR was particularly reflected in the percentage of nonevents correctly reclassified (44%), whereas the percentage of events reclassified was Ϫ16%. Compared with cystatin C, BTP had a net reclassification improvement of 0, with an integrated discrimination improvement of 0.00008; compared with cystatin C, BTP had a 0% reclassification of either events or nonevents, indicating that BTP offered information comparable to that of cystatin C.
In univariable Cox regression analysis, all measures of kidney function were associated with a higher risk of adverse clinical events (Table 5 ). However, after adjusting for confounding factors in the multivariable Cox regression models, only BTP and cystatin C concentrations remained as significant predictors of adverse events, whereas creatinine, eGFR, and BUN were no longer significant (Table 5 ). This remained the case when measurements of renal function were evaluated as dichotomous variables in multivariate Cox regression models: BTP and cystatin C were significant predictors of mortality and/or HF readmission (HR: 1.54, 95% CI: 1.10 to 2.38; p ϭ 0.02 for BTP Ͼ0.96 mg/l and HR: 1.73, 95% CI: 1.15 to 2.62; p ϭ 0.009 for cystatin C Ͼ1.05 mg/l), but creatinine, eGFR, and BUN were not (p Ͼ 0.2). Furthermore, when BTP and cystatin C were adjusted for other conventional measures of kidney function, both remained associated with a higher risk of adverse events (log 10 BTP, HR: 3.01, 95% CI: 1.08 to 7.87, p ϭ 0.033 and log 10 cystatin C, HR: 3.56, 95% CI: 1.22 to 9.35, p ϭ 0.018).
As shown in the Kaplan-Meier survival analyses, increased BTP concentration (Ͼ0.96 mg/l) and elevated cystatin C concentration (Ͼ1.05 mg/l) were associated with an increased risk of adverse clinical events (Fig. 3) (log-rank test, p Ͻ 0.05). In stratified analyses of patients with an eGFR Ͼ60 ml/min/1.73 m 2 (n ϭ 146), increased BTP and cystatin C concentrations were also found to be associated with a higher mortality and/or HF hospitalization risk (Fig. 4) (log-rank test, p Ͻ 0.05).
Discussion
The importance of parameters of renal function in ADHF is considerable. Indeed, kidney dysfunction represents one of the most dominant variables for predicting adverse outcome in patients with ADHF (22, 23) . Although powerfully predictive of adverse outcome, conventional tests for Box plots of the concentrations of ␤-trace protein (A) and cystatin C (B) in patients who died and/or were hospitalized for heart failure (HF) and those who did not experience adverse clinical events. The bottom and top whiskers indicate the 5th and 95th percentile levels; the lower and upper boundaries of the boxes, the 25th and 75th percentile levels; and the horizontal line within the box, the median level.
Figure 2 Mortality and/or HF Hospitalization as a Function of BTP and Cystatin C Tertiles
Rates of mortality and/or heart failure (HF) hospitalization were significantly higher with increasing concentrations of both ␤-trace protein (BTP) (p ϭ 0.008) and cystatin C (p Ͻ 0.001).
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In this study, we examined novel markers of renal dysfunction, BTP, and cystatin C and compared them with conventional measures of renal function for their ability to predict adverse outcome. Neither BTP nor cystatin C at presentation (or other measures of renal function) predicted the onset of renal dysfunction after presentation with ADHF. This suggests that baseline renal function may be less important for predicting subsequent worsening in glomerular filtration rate (GFR) than are the various clinical and therapeutic insults that occur in patients with ADHF that may lead to such a decline. On the other hand, consistent with previous reports (5-13), we found cystatin C to independently predict death/HF hospitalization with greater accuracy than creatinine, eGFR, or BUN; moreover, BTP performed comparably to cystatin C for this indication. Of special note, among patients with an eGFR Ͼ60 ml/min (an area of weakness for serum creatinine and eGFR), we found that increased concentrations of both BTP and cystatin C were still associated with significantly higher risk of adverse clinical events. To the best of our knowledge, this is the first study to describe the prognostic usefulness of BTP in ADHF.
Over the past years, kidney dysfunction, including mild and moderate chronic kidney disease, has become increasingly recognized as an independent risk factor for morbidity and mortality in patients with HF (22) (23) (24) (25) (26) (27) (28) . A recent meta-analysis (29) showed that the majority of patients with HF had some degree of renal impairment, and these patients represent a high-risk group with an approximately 50% increased relative mortality risk compared with patients with normal kidney function. Because serum creatinine, eGFR equations, and BUN are insensitive to mild decrements in renal function (2-4), the detection of mild kidney dysfunction in routine clinical practice remains challenging. It has been suggested that BTP and cystatin C concentrations are more sensitive for the detection of mild decrements The p values shown are for comparison among ␤-trace protein and other variables. ADHF ϭ acutely destabilized heart failure; AUC ϭ area under the curve; CI ϭ confidence interval; NPV ϭ negative predictive value; PPV ϭ positive predictive value; other abbreviations as in Tables 1 and 2 . Log 10 ␤-trace protein, log 10 cystatin C, log 10 creatinine, and log 10 eGFR were all tested separately and multivariable hazard ratios and p values for other variables shown from the ␤-trace protein model. Abbreviations as in Tables 1 and 2 . of GFR (15) (16) (17) 30, 31) . Consistent with this suggestion, we found both BTP and cystatin C to be independently superior to standard measures of renal function for predicting death and/or HF hospitalization. Given the reported value of conventional measures of renal function for prognostication in patients with ADHF (22, 23) , our findings are of significance. BTP is a low-molecular weight glycoprotein, belonging to the lipocalin protein family, with a molecular weight of 22 to 29 kDa depending on the degree of glycosylation (32, 33) . BTP is synthesized in the central nervous system, male genital organs, and heart and is secreted into the cerebrospinal fluid, seminal plasma, and plasma, respectively (34 -36). Hoffmann et al. (33) showed that "brain type" BTP is absent in serum and urine (because it is cleared by the liver via specific hepatic glycoprotein receptors), whereas sialyzed glycoforms are protected against hepatic metabolism and are eliminated via glomerular filtration, allowing for sensitive estimation of renal function.
Cox Regression Risk Analysis for Prediction of Mortality and/or HF Hospitalization
As mentioned previously, plasma BTP concentration appears superior to standard means of renal function estimation for the detection of mild decrements of GFR. Thus, our results might indicate that the risk of adverse events attributable to kidney disease is not completely captured by estimates of kidney function routinely used in clinical practice. On the other hand, BTP has also been implicated in numerous other physiologic and pathologic processes including inflammatory responses (37), endo- Manzano-Ferná ndez et al. February 15, 2011:849-58 ␤-Trace Protein, Cystatin C, and Acute Heart Failure thelial cell function (38) , atherogenesis (36, 39) , insulin sensitivity (40) , and systemic arterial hypertension (41) . We therefore cannot exclude the possibility that circulating BTP concentrations reflect (directly or indirectly) pathophysiologic processes pivotal to HF progression. Cystatin C is a low-molecular weight protein (13 kDa) that is released at a constant rate and expressed in all nucleated cells (42) . It has multiple biological functions, including controlling extracellular proteolysis via inhibition of cysteine peptidases (especially cathepsins B, H, L, and S) (43), modulation of the immune system (44), exertion of antibacterial and antiviral activities, and modification of the body's response to brain injury. Cystatin C is freely filtrated in the glomerulus and subsequently absorbed in the renal tubules where it is fully degraded locally, without reentering the bloodstream. No active tubular secretion or significant extrarenal elimination occurs (45, 46) . Therefore, plasma cystatin C concentration is mainly dependent on the GFR. Although several previous studies have shown that plasma cystatin C concentration predicts adverse clinical outcomes across a wide spectrum of patients including those with HF (5-13), it also remains unclear, however, whether the association with adverse outcomes is due to cystatin C being a more precise measure of kidney function or whether cystatin C is a reflection of other pathologic processes independent of the GFR. Importantly, cystatin C has not been previously compared with BTP as a prognostic risk factor, so the present study adds to the existing literature by demonstrating that BTP is at least comparable to cystatin C for predicting adverse clinical events in hospitalized patients with ADHF. Study limitations. The limitations of our study are similar to those of any single-center prospective, observational study. The small sample size and relatively small number of patients included in each group also make it difficult to draw firm conclusions. In this study, we included unselected hospitalized patients with ADHF due to both systolic and nonsystolic mechanisms, so the validity of our findings in selected HF populations remains to be established. In addition, the presence of unmeasured variables such as activity of coronary ischemia, diastolic abnormalities, and severity of valvular heart disease were not factored into our multivariable Cox regression analyses for prediction of poor outcomes. For the prediction of outcomes, the number of covariates included in multivariable models was Ͼ1 for each 10 events. Therefore, it remains possible that the models were overadjusted, and consequently our results could fail to be replicated in future samples. In our study cohort, we found that increased plasma NT-proBNP concentration did not predict adverse clinical events beyond cystatin C and BTP. However, because several previous studies have demonstrated that NT-proBNP and cystatin C concentrations offered complementary prognostic value in this clinical setting (5, 11, 12) , we cannot exclude that our results may represent a false-negative (type II) error due to overadjustment of covariates in the context of a relatively small number of subjects with ADHF. Furthermore, we also found that worsening of renal function was not associated with adverse clinical events after adjustment for baseline clinical and biochemical risk factors. This likely reflects the dominance of baseline novel renal function parameters over a worsening of renal function definition based on an absolute increase in serum creatinine during hospitalization. Last, we do not have follow-up (post-treatment) values for measures of renal function; such follow-up values would be expected to provide further prognostic information about our patients.
Conclusions
In patients with ADHF, BTP and cystatin C appear to add comparable and significant prognostic value and were superior to creatinine, eGFR, and BUN, each a well-established prognostic variable in this context.
